BRAF and melanoma: Regarding the high incidence of B-Raf mutations and the increased expression level in tumors, B-Raf should be an attractive target for immunotherapy [17] and most recently, independent findings demonstrated mutation specific CD4+ T-cell responses in melanoma patients [18].